Noncompliance with protocol, SOPs, GCP, or regulatory requirements by an investigator or sponsor staff should lead to what action?

• A. Prompt action by the sponsor to secure compliance.
• B. Do nothing until problems worsen.
• C. Only terminate the trial.
• D. Publicly disclose the noncompliance.

Answer: (A)

When noncompliance with the protocol, SOPs, GCP, or regulatory requirements is identified, the sponsor must act promptly to bring the study back into compliance and protect participant safety and data integrity. The sponsor’s immediate steps involve initiating corrective and preventive actions (CAPA), reviewing the deviation to assess its impact on subject safety and data, and communicating with the investigator and site staff to implement fixes—such as retraining, protocol or SOP updates, and enhanced monitoring. If necessary to protect participants, the sponsor may suspend or modify activities at the site or even halt the trial, but the first and most appropriate response is to secure compliance quickly. Delaying action risks participant safety and data reliability, while public disclosure or automatic termination aren’t the required first steps unless specified by regulatory or safety concerns; those actions may follow after the initial CAPA and containment measures.